Alirocumab Response in FRG Mice

Regulation of Lipoprotein (a) Metabolism by PCSK9 in Animal Models

Villard et. al., 2016

Study Summary

T. T. T. Tran, E. Villard, B. Poirier, E. Guillot, JC. Le Bail, C. Boixel, D. Boulay, J. Blankenstein, A. Parkar, T. Muslin and P. Janiak

Sanofi Poster.

Study Abstract

Low density liprotein-cholesterol (LDL-C), a major risk factor for coronary heart disease, is a primary interventional target for lipid-lowering PCSK9 antibodies such as Alirocumab.  In contrast to statins, Alirocumab also significantly reduces plasma lipoprotein (a) (Lp(a)) in patients, another independent risk factor of cardiovascular diseases including aortic valve stenosis.  FRG KO mice and non-human primates are utilized to demonstrate that liver humanized mouse models faithfully recapitulate that Aliorocumab decreased plasma LDL-C and Lp(a) levels.

PUT OUR EXPERIENCE TO WORK FOR YOU

Subscribe For News and Information

Join our mailing list to receive the latest news and updates, sales promotions, and job opportunies.

You have Successfully Subscribed!